These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 23841506)

  • 21. Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia.
    Thota S; Advani A
    Eur J Haematol; 2017 May; 98(5):425-434. PubMed ID: 28152223
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The ABCs of Immunotherapy for Adult Patients With B-Cell Acute Lymphoblastic Leukemia.
    Horvat TZ; Seddon AN; Ogunniyi A; King AC; Buie LW; Daley RJ
    Ann Pharmacother; 2018 Mar; 52(3):268-276. PubMed ID: 29025266
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Developing novel strategies to target B-cell malignancies.
    Fowler N; Oki Y
    Am Soc Clin Oncol Educ Book; 2013; ():366-72. PubMed ID: 23714549
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia.
    DasGupta RK; Marini BL; Rudoni J; Perissinotti AJ
    J Oncol Pharm Pract; 2018 Sep; 24(6):453-467. PubMed ID: 28583018
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of relapsed acute lymphoblastic leukemia in childhood with conventional and innovative approaches.
    Locatelli F; Moretta F; Rutella S
    Curr Opin Oncol; 2013 Nov; 25(6):707-15. PubMed ID: 24076579
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past.
    Short NJ; Kantarjian H
    Lancet Haematol; 2023 May; 10(5):e382-e388. PubMed ID: 37003279
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults.
    Ronson A; Tvito A; Rowe JM
    Curr Oncol Rep; 2016 Jun; 18(6):39. PubMed ID: 27207612
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted therapy paves the way for the cure of acute lymphoblastic leukaemia.
    Rafei H; Kantarjian HM; Jabbour EJ
    Br J Haematol; 2020 Jan; 188(2):207-223. PubMed ID: 31566728
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inotuzumab Ozogamicin: A Review in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia.
    Al-Salama ZT
    Target Oncol; 2018 Aug; 13(4):525-532. PubMed ID: 30090971
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia.
    Shi Z; Zhu Y; Zhang J; Chen B
    Hematology; 2022 Dec; 27(1):642-652. PubMed ID: 35622074
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monoclonal antibodies and immune therapies for adult precursor B-acute lymphoblastic leukemia.
    Sikaria S; Aldoss I; Akhtari M
    Immunol Lett; 2016 Apr; 172():113-23. PubMed ID: 26921100
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Humoral and cellular immunotherapy in ALL in children, adolescents, and young adults.
    Hochberg J; El-Mallawany NK; Cairo MS
    Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S6-13. PubMed ID: 25486958
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent advances in the treatment of acute lymphoblastic leukemia.
    Rafei H; Kantarjian HM; Jabbour EJ
    Leuk Lymphoma; 2019 Nov; 60(11):2606-2621. PubMed ID: 31092071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.
    Goebeler ME; Bargou R
    Leuk Lymphoma; 2016 May; 57(5):1021-32. PubMed ID: 27050240
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug development: target practice.
    Katsnelson A
    Nature; 2013 Jun; 498(7455):S8-9. PubMed ID: 23803950
    [No Abstract]   [Full Text] [Related]  

  • 36. Structure, development, preclinical and clinical efficacy of blinatumomab in acute lymphoblastic leukemia.
    Bumma N; Papadantonakis N; Advani AS
    Future Oncol; 2015; 11(12):1729-39. PubMed ID: 26075441
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current and future management of Ph/BCR-ABL positive ALL.
    Maino E; Sancetta R; Viero P; Imbergamo S; Scattolin AM; Vespignani M; Bassan R
    Expert Rev Anticancer Ther; 2014 Jun; 14(6):723-40. PubMed ID: 24611626
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia.
    Bertamini L; Nanni J; Marconi G; Abbenante M; Robustelli V; Bacci F; Matti A; Paolini S; Sartor C; Monaco SL; Fontana MC; De Polo S; Cavo M; Curti A; Martinelli G; Papayannidis C
    BMC Cancer; 2018 Nov; 18(1):1117. PubMed ID: 30442119
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia.
    Tvito A; Rowe JM
    Expert Opin Biol Ther; 2017 Dec; 17(12):1557-1564. PubMed ID: 29092647
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia.
    Le Jeune C; Thomas X
    Drug Des Devel Ther; 2016; 10():757-65. PubMed ID: 26937176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.